Scope
- Therapy Remove Therapy filter
- Quality of care research (5) Apply Quality of care research filter
- Epidemiology (4) Apply Epidemiology filter
- Public Administration (3) Apply Public Administration filter
- Pharmacoeconomic (2) Apply Pharmacoeconomic filter
- Safety (2) Apply Safety filter
- Diagnosis (1) Apply Diagnosis filter
- Pharmacogenetic (1) Apply Pharmacogenetic filter
- Pharmacogenomic (1) Apply Pharmacogenomic filter
- Pharmacovigilance (1) Apply Pharmacovigilance filter
Commissioners
- National Institute for Health and Disability Insurance (5) Apply National Institute for Health and Disability Insurance filter
- Anouk Waeytens (1) Apply Anouk Waeytens filter
- Christiaan Decoster (1) Apply Christiaan Decoster filter
- Federal Public Service Health, Food Chain Safety and Environment (1) Apply Federal Public Service Health, Food Chain Safety and Environment filter
- Greet Haelterman (1) Apply Greet Haelterman filter
- Pierre Bonte (1) Apply Pierre Bonte filter
Careprovider
- General hospitals (3) Apply General hospitals filter
- Unknown (3) Apply Unknown filter
- University hospitals (2) Apply University hospitals filter
- Laboratories: anatomical pathology (1) Apply Laboratories: anatomical pathology filter
- Laboratories: clinical biology (1) Apply Laboratories: clinical biology filter
- Laboratories: human genetics (1) Apply Laboratories: human genetics filter
Caregiver
Sponsors
- National Institute for Health and Disability Insurance (3) Apply National Institute for Health and Disability Insurance filter
- AbbVie (1) Apply AbbVie filter
- Anne Clerx (1) Apply Anne Clerx filter
- Bristol-Meyers-Squibb (1) Apply Bristol-Meyers-Squibb filter
- Federal Public Service Health, Food Chain Safety and Environment en National Institute for Health and Disability Insurance (1) Apply Federal Public Service Health, Food Chain Safety and Environment en National Institute for Health and Disability Insurance filter
- Gilead Sciences (1) Apply Gilead Sciences filter
- Janssen Pharmaceutica (1) Apply Janssen Pharmaceutica filter
- Merck Sharp Dohme (1) Apply Merck Sharp Dohme filter
Support
- National Institute for Health and Disability Insurance (4) Apply National Institute for Health and Disability Insurance filter
- AbbVie (1) Apply AbbVie filter
- Bristol-Meyers-Squibb (1) Apply Bristol-Meyers-Squibb filter
- Federal Public Service Health, Food Chain Safety and Environment (1) Apply Federal Public Service Health, Food Chain Safety and Environment filter
- Gilead Sciences (1) Apply Gilead Sciences filter
- Janssen Pharmaceutica (1) Apply Janssen Pharmaceutica filter
- Merck Sharp Dohme (1) Apply Merck Sharp Dohme filter
Registration projects in health and health care
The Belgian Obstetric Surveillance System, B.OSS, supported by the College of Mother and Newborn, has been constituted in 2011 and started registering in the whole of Belgium as from January 2012. Meanwhile, the registration and evaluation of some diseases or rare complications in pregnancy has become a widely accepted practice in Belgium. Belgian gynaecologists are happy to receive advice based on own data, because practice in Belgium and certainly the organization of medical care do differ from that used in neighbouring countries. Whereas Peristat (...
No information available
Currently the reimbursement of personalized medicines is not coupled with that of the accompanying biomarker which often leads to a delay in reimbursement of the predictive tests as compared to the personalized medicine. To better align reimbursement of the medicine and the predictive test, a coupled reimbursement procedure[1],[2] will be created that will allow a monthly update of reimbursed personalized medicines and their corresponding predictive test, and as such will be flexible enough to adjust for the rapid evolving field...
No information available
The reimbursement conditions for 6 specific types of antiviral hepatitis C medication for the treatment of chronic hepatitis C patients will be extended and 2 new ones will be added[1]. This extended reimbursement will be active starting from 1.1.2017 and is agreed upon for a period of 2 years between RIZIV-INAMI and the 5 involved pharmaceutical companies via a contract of type Art.81 signed with the RIZIV-INAMI..
The hepatitis C antiviral medication is on the list of Chapter 4 medication, which requires the treating physician to fill out a...